<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Side Effects</title>
	<atom:link href="http://www.psa-rising.com/blog/category/ca/ca-tx/side-effects/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Tue, 16 Aug 2011 09:39:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/#comments</comments>
		<pubDate>Thu, 20 Aug 2009 12:48:46 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Denosumab]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[trial results]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1425</guid>
		<description><![CDATA[Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. Matthew R. Smith and an international team investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/08/denosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Proton Therapy On Pres. Obama&#8217;s Health-Care Hatchet List?</title>
		<link>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/</link>
		<comments>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 14:34:47 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Beam Radiation]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Proton]]></category>
		<category><![CDATA[Side Effects]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1318</guid>
		<description><![CDATA[Proton beam therapy for prostate cancer, a treatment that attracts more than an average numbers of engineers, scientists and pilots, is coming under intense scrutiny from reporters who expect it to be questioned by the Obama adminstration&#8217;s health-care reform team. In an article in today&#8217;s New York Times, &#8220;In Health Reform, a Cancer Offers an [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/07/is-proton-beam-therapy-on-obamas/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bisphosphonate Side Effects and a New Clinical Trial</title>
		<link>http://www.psa-rising.com/blog/2009/01/bisphosphonates/</link>
		<comments>http://www.psa-rising.com/blog/2009/01/bisphosphonates/#comments</comments>
		<pubDate>Thu, 01 Jan 2009 06:40:48 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Bisphosphonates]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Chemotherapy]]></category>
		<category><![CDATA[Esophageal]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[Fosamax]]></category>
		<category><![CDATA[rHuPH20]]></category>
		<category><![CDATA[Zometa]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=890</guid>
		<description><![CDATA[Recent stories on bisphosphonate side effects might be signaling the advent of a new, superior drug, but will Halozyme&#8217;s rHuPH20 enzyme solve the problem of jaw necrosis? Drug development companies operate within the overall consumer culture. We all want better drugs, better everything. Generic Fosamax (alendronate) now costs just $4 at Wal-Mart, Kroger and other [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/01/bisphosphonates/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Fosamax Linked to Esophageal Cancer</title>
		<link>http://www.psa-rising.com/blog/2008/12/fosamax-linked-to-esophageal-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2008/12/fosamax-linked-to-esophageal-cancer/#comments</comments>
		<pubDate>Thu, 01 Jan 2009 00:41:27 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Bisphosphonates]]></category>
		<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Esophageal]]></category>
		<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[Fosamax]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=879</guid>
		<description><![CDATA[Diane Wysowski of the FDA&#8217;s division of drug risk assessment says researchers should check into potential links between oral bisphosphonate drugs and cancer of the esophagus. Merck&#8217;s oral osteoporosis drug Fosamax may carry a risk for esophageal cancer, Wysowski writes in a letter to January 1, 2009 New England Journal of Medicine. Bisphosphonates are a [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2008/12/fosamax-linked-to-esophageal-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Clinical Sexologist and Therapist Joins Krongrad Institute</title>
		<link>http://www.psa-rising.com/blog/2008/11/clinical-sexologist-and-therapist-joins-krongrad-institute/</link>
		<comments>http://www.psa-rising.com/blog/2008/11/clinical-sexologist-and-therapist-joins-krongrad-institute/#comments</comments>
		<pubDate>Mon, 24 Nov 2008 05:56:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[ED]]></category>
		<category><![CDATA[Erectile dysfunction]]></category>
		<category><![CDATA[intimacy]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Penile rehab]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[QOL]]></category>
		<category><![CDATA[Side Effects]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=583</guid>
		<description><![CDATA[Rhonda Fine PhD ARNP Many factors can adversely affect sexual performance. Physical disability illness, obesity, medications, aging, stress, grief, emotional distress and relationship conflicts may all at times contribute to sexual dysfunction. Prostate cancer diagnosis and treatment may also contribute to sexual dysfunction. To help men and their partners cope with and manage sexual dysfunction, [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2008/11/clinical-sexologist-and-therapist-joins-krongrad-institute/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prostate Cancer and Masculinity</title>
		<link>http://www.psa-rising.com/blog/2008/11/prostate-cancer-and-masculinity/</link>
		<comments>http://www.psa-rising.com/blog/2008/11/prostate-cancer-and-masculinity/#comments</comments>
		<pubDate>Mon, 24 Nov 2008 02:36:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Advocacy]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[QOL]]></category>
		<category><![CDATA[Side Effects]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=566</guid>
		<description><![CDATA[BY CHARLES (CHUCK) MAACK – Prostate Cancer Advocate In opening: The capability to have an erection does not define what constitutes the title “Man.” I’ve become exasperated reading of men claiming they are less a man because they are unable to get an erection or have lost libido/potency. &#8220;I’m less a man,&#8221; &#8220;I’m a eunuch,&#8221; [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2008/11/prostate-cancer-and-masculinity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amgen claims &#8220;neutral&#8221; effect for Aranesp</title>
		<link>http://www.psa-rising.com/blog/2007/04/amgen-claims-neutral-effect-for-aranesp/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/amgen-claims-neutral-effect-for-aranesp/#comments</comments>
		<pubDate>Fri, 20 Apr 2007 09:12:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Side Effects]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[anemia]]></category>
		<category><![CDATA[Aranesp]]></category>
		<category><![CDATA[fatigue]]></category>
		<category><![CDATA[thrombosis]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/20/amgen-claims-neutral-effect-for-aranesp/</guid>
		<description><![CDATA[Anemia drugs may be safer for cancer patients to take than recenty thought. This week Amgen released data showing that its anemia dug Aranesp (darbepoetin alfa) did not increase risk of death when used with platinum chemotherapy by patients with extensive small-cell lung cancer (SCLC), but nor did the anti-anemia drug improve patients&#8217; survival. This [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/amgen-claims-neutral-effect-for-aranesp/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

